Regulation of advanced therapy medicinal products will affect the practice of haematopoietic SCT in the near future: A perspective from the EBMT cell-processing committee

Bone Marrow Transplantation

Volumn 50, Issue 3, 2015, Pages 321-323

  Chabannon, C ^a,b,c,d   Hildebrandt, M ^a,e   Scheding, S ^a,f   Humpe, A ^a,g   Lowdell, M ^a,h   Slaper Cortenbach, I ^a,i  

^a EBMT Secretariat   (Spain)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d INSERM   (France)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h ROYAL FREE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EDITORIAL; GOOD MANUFACTURING PRACTICE; HUMAN; MEDICAL PRACTICE; MEDICAL RESEARCH; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REGENERATIVE MEDICINE; TREATMENT INDICATION; TREATMENT PLANNING; ALLOTRANSPLANTATION; FINANCIAL MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; PROCEDURES; STANDARDS;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MARKETING OF HEALTH SERVICES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84938414967     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.271     Document Type: Editorial

References (18)

1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med 2007; 357: 1472-1475.
2. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012; 47: 906-923.
3. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-234.
4. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 2011; 29: 1980-1986.
5. European Commission Regulation (EC) No 1394/2007 of The European Parliament and of The Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324: 0121:0137:en:PDF).
6. Pearce KF, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N et al. Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy 2013; 16: 289-297.
7. European Medicines Agency Scientific recommendation on classification of advanced therapy medicinal products. Available at http://www.ema.europa.eu/ docs/en-GB/document-library/Report/2013/05/WC500143582.pdf 2013.
8. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 2008; 41: 771-778.
9. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367: 2305-2315.
10. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232-236.
11. Reiffers J, Cailliot C, Dazey B, Attal M, Caraux J, Boiron JM. Abrogation of postmyeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet 1999; 354: 1092-1093.
12. Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol 2013; 163: 501-509.
13. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
14. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013; 122: 2965-2973.
15. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra225.
16. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
17. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360-4367.
18. European Commission Report from the Commission to the European Parliament and the Council in accordance with Article 25 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (http://ec.europa.eu/health/files/advtherapies/2014-atmp/atmp-en.pdf 2014).